Association of p16 and Ki-67 with Risk of Recurrence in Previously Treated Cervical High-Grade Squamous Intraepithelial Lesions
Por:
Arredondo-Galvez, Carlos German, Acuna-Gonzalez, Denise, Cantu-de-Leon, David, Chanona-Vilchis, Jose Gregorio, Aviles-Salas, Alejandro, Gonzalez-Enciso, Aaron, Bandala-Jaques, Antonio, Barquet-Munoz, Salim Abraham
Publicada:
1 jul 2021
Ahead of Print:
1 jun 2021
Resumen:
Objective: Our main objective was to assess the association between the
markers p16 and Ki-67 and recurrence of disease in patients previously
treated for cervical high-grade squamous intraepithelial lesion (HSIL).
Design: This is a case-control study at the National Cancer Institute
conducted between 2005 and 2015. Of the patients with a pathologically
confirmed diagnosis of HSIL, 107 cases were selected. They were divided
into 2 groups: 28 cases with recurrence after treatment and a control
group of 79 patients without recurrence. We identified clinical,
pathological, and treatment variables. Methods: Two experienced
pathologists performed immunohistochemical analysis of biomarkers; they
agreed on their interpretation, and we calculated the odds ratios (ORs)
associated with recurrence. For group comparisons, we used the Wilcoxon
signed-rank, chi(2), or Fisher's exact test, depending on the type of
variable. We conducted logistic regression models to estimate ORs and
determine the factors associated with recurrence. The recurrence-free
period was defined as the time frame between conization and either
recurrence of disease or the last date the patient was seen. We used
Kaplan-Meier plots to visualize survival curves and log-rank tests to
compare the curves. We established a p value Results: After pathologists
performed immunohistochemical analysis, they achieved an agreement level
of 83.7% for p16 and 60% for Ki-67. We did not find an association
between recurrence and either p16 expression (p = 0.69) or the
percentage of Ki-67 expression (p = 0.71). The recurrence-free period
analysis did not reveal a difference in p16 expression (p = 0.57) nor in
the percentage of Ki-67 expression in the 3-tiered scale (p = 0.56).
Limitations: Our main limitation was a reduced sample size. Conclusion:
We found no association between p16 and Ki-67 positivity and the risk of
recurrence in previously treated HSIL.
Filiaciones:
Arredondo-Galvez, Carlos German:
Inst Nacl Cancerol, Dept Ginecol, Mexico City, DF, Mexico
Acuna-Gonzalez, Denise:
Ctr Med Naval, Dept Ginecol, Mexico City, DF, Mexico
Cantu-de-Leon, David:
Inst Nacl Cancerol, Unidad Invest Biomed Canc, Mexico City, DF, Mexico
Univ Nacl Autonoma Mexico, Inst Invest Biomed, Mexico City, DF, Mexico
Aviles-Salas, Alejandro:
Inst Nacl Cancerol, Dept Patol, Mexico City, DF, Mexico
Gonzalez-Enciso, Aaron:
Inst Nacl Cancerol, Subdirecc Cirugia, Mexico City, DF, Mexico
Bandala-Jaques, Antonio:
Inst Nacl Cancerol, Unidad Invest Biomed Canc, Mexico City, DF, Mexico
Univ Nacl Autonoma Mexico, Inst Invest Biomed, Mexico City, DF, Mexico
Barquet-Munoz, Salim Abraham:
Inst Nacl Cancerol, Dept Ginecol, Mexico City, DF, Mexico
|